

Experience Of Combined Use of Risperidone with Nootropic Drugs in Complex Therapy of Patients with Paranoid Schizophrenia with An Ideation Pattern of Non-Suicidal Auto-Aggressive Behavior

Vinnikova I.N ¹, Kravchenko I.V ^{2*}

¹Federal state budgetary institution "National Medical Research Center for Psychiatry and Narcology named after V. P. Serbsky" of the Ministry of Health of the Russian Federation.

²Interdistrict Center for Medical Rehabilitation at the State Budgetary Healthcare Institution "Polyclinic N38", St. Petersburg, Russia; Interdistrict Center for Medical Rehabilitation.

*Correspondence Author: Kravchenko I.V, Interdistrict Center for Medical Rehabilitation at the State Budgetary Healthcare Institution "Polyclinic N38", St. Petersburg, Russia; Interdistrict Center for Medical Rehabilitation

Received Date: June 10, 2024 | Accepted Date: June 28, 2024 | Published Date: July 09, 2024

Citation: Vinnikova I.N, Kravchenko I.V, (2024), Experience of Combined Use of Risperidone with Nootropic Drugs in Complex Therapy of Patients with Paranoid Schizophrenia with An Ideation Pattern of Non-Suicidal Auto-Aggressive Behavior, *Clinical Reviews and Case Reports*, 3(4); DOI:10.31579/2835-7957/091

Copyright: © 2024, Kravchenko I.V. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Paranoid schizophrenia is characterized by polymorphism of clinical manifestations and the difficulty of curing negative disorders. To increase the effectiveness of therapy, it is theoretically justified to simultaneously prescribe antipsychotic and nootropic drugs. Based on the example of the combined use of risperidone, memantine and choline alfoscerate in various combinations, data were obtained on increasing the effectiveness of therapy in relation to positive and negative disorders, including non-suicidal auto-aggressive behavior (NAAB). At the same time, the first-line therapy in such patients is the simultaneous administration of all three drugs included in the study - risperidone, choline alfoscerate and memantine.

Keywords: risperidone; choline alfoscerate; memantine; paranoid schizophrenia; non-suicidal auto-aggressive behavior

Introduction

Schizophrenia remains a disease with an unclear etiology and pronounced polymorphism of clinical manifestations. Antipsychotic drugs retain their leading role in the treatment of such patients. However, if they demonstrate high effectiveness in relation to positive disorders, then in relation to the correction of negative manifestations their effect is not enough. In turn, discussions continue in the scientific community regarding the etiology and pathogenesis of negative disorders themselves, including neurocognitive changes. An additional clinical problem is the clinical pathomorphosis of the schizophrenic process. In particular, the proportion of affective and behavioral disorders, including non-suicidal auto-aggressive behavior or "NAAB", is steadily increasing [1]. To solve these clinical problems, combination therapy regimens are increasingly being used, where nootropic drugs act as adjuvant drugs to neuroleptics. Among them, the first line includes drugs whose mechanism of action is associated with an effect on the glutamatergic and cholinergic systems. Thus, the drug Memantine has a multimodal effect in relation to the hypothetical pathogenetic links of the schizophrenic process. In addition to its main function as an antagonist of NMDA receptors, memantine prevents oversaturation of the intracellular space with calcium ions, modulates the activity of the cholinergic, serotonergic and dopaminergic systems, as well as providing an immunomodulatory effect [2,3,4,5,6,7,8,9, 10,11,12,13,14,15,16]. Disturbances of the cholinergic system are

observed in almost all mental disorders, including schizophrenia. This predetermines the active use of drugs with cholinergic activity in the treatment of schizophrenia spectrum disorders [17,18,19,20]. In practice, encouraging results were obtained when combining antipsychotics with individual nootropic drugs [21,22,23,24]. A natural continuation of the work of researchers to optimize the treatment of patients with schizophrenia was the attempt to combine antipsychotics with several nootropic drugs. Among the latter, preference has traditionally been given to memantine and galantamine, as the most studied pharmacological agents [25,26,27,28,29]. This study is an attempt to continue the clinical search for combined treatment regimens with neuroleptics and nootropic drugs for the correction of leading psychopathological manifestations including non-suicidal auto-aggressive actions (NAAA) in patients with paranoid schizophrenia.

Purpose of the study: to study the effectiveness of the combined use of risperidone with nootropic nootropic drugs in patients with paranoid schizophrenia with the ideation pattern of NAAB.

Objectives of the study: 1) to study the effect of nootropic drugs on the nature of clinical and psychopathological manifestations in patients with paranoid schizophrenia with NAAB; 2) to study the effect of nootropics on social adaptation in patients with paranoid schizophrenia with NAAB;

2) study the effect of nootropic drugs on the frequency of NAAA in such patients.

Material and research methods. A total of 81 patients with paranoid schizophrenia were studied in a comparative, non-randomized manner. The average age of the subjects was 35.2 ± 1.3 years, the duration of the disease was 15.6 ± 2.2 years. All examined were men. Type of course of the schizophrenic process: continuous - progressive. The inclusion criteria were: 1) compliance of the diagnosis of paranoid schizophrenia with the criteria of the ICD-10 revision (F20.0); 2) a state of drug remission, with signs of an increasing procedural personality defect; 3) implementation of NAAD by patients with a history of paranoid schizophrenia. Non-inclusion criteria were: 1) psychotic level of disorders at the time of inclusion in the study; 2) auto-aggressive actions in the form of self-strangulation as a means of obtaining sexual satisfaction (asphyxiophilia); 3) taking the drugs included in the study less than 6 months before the start of the study itself. By remission was meant "the weakening and mitigation of all symptoms, ensuring, to one degree or another, the social and labor adaptation of the patient, and embracing a wide range of conditions from those bordering on practical recovery to those in which the symptoms of the defect are already clearly visible" [30]. A schizophrenic defect, or in the modern interpretation – neuro-cognitive procedural changes, was understood as "the consequences of a mental illness that occur in conditions of a complete stop of the process, lead to a persistent (and non-progressive) loss or dissociation of mental functions with a change in personality and are accompanied by a decrease in its functioning" [30]. The definition of "NAAA" included a variety of actions directed against one's health and accompanied by a violation of the integrity (functions) of organs or organ systems. At the same time, there was no demonstration of intention to commit suicide [31]. The study included a main group and a comparison group. The main group consisted of subjects (21 people) who were on monotherapy with risperidone, the average daily dose of which was 7.8 ± 0.4 mg. The comparison group consisted of patients taking combination therapy regimens, including risperidone, choline alfoscerate and memantine. Next, the comparison group was divided into 4 subgroups. The first subgroup (17 people) took risperidone and choline alfoscerate in average daily doses: risperidone -7.7 ± 0.3 mg, choline alfoscerate 800 mg. The second subgroup (21 people) took risperidone and memantine in average daily doses: risperidone -7.8 ± 0.3 mg and memantine 10 mg. The third subgroup (22 people) took risperidone, choline alfoscerate and memantine simultaneously, in average daily doses: risperidone -7.8 ± 0.3 mg, choline alfoscerate 800 mg, memantine 10 mg. The choice of drugs for the study was determined by their most frequent use in practical work with this category of patients. The assessment of the mental state of the examination was carried out using a clinical method at the time of inclusion in the study (1 week), then at weeks 12 and 24 of the study. The clinical effectiveness of therapy was determined by comparative analysis of the frequency of exacerbation of psychotic symptoms and committed acts of non-suicidal auto-aggression for a period of 24 weeks before and after inclusion in the study. To objectify the data obtained, the Scale of Negative Psychopathological Symptoms (SANS) was used. Fisher's test was used for statistical evaluation. The clinical and psychopathological picture of the course of the disease consisted of a combination of positive and negative disorders. A retrospective analysis showed that the prodromal period averaged 4.8 ± 0.3 years. During this period, there were causeless mood swings, predominantly of the hypothymic type; Occasionally, patients experienced a feeling of protopathic anxiety. Unmotivated outbursts of aggression with self-harm were noted, including both NAAA (burning the skin, scratching the skin) and impulsive suicide attempts. The patients themselves noted that "during this period of time it became more difficult to assimilate new educational material, thoughts were sometimes "confused." During the 6-12 months preceding the first psychotic episode, depression increased, interspersed with outbursts of irritability and openly displayed aggression (they broke things, fought with relatives). They impulsively began to consume psychoactive substances, immediately

reaching high doses; The intake was carried out continuously, and their consumption was also abruptly interrupted. At the same time, no manifestations of withdrawal syndrome and subsequent mental and physical dependence were observed. Outside the stage of drug intoxication, transient illusions of perception and mental automatisms were experienced. Thus, patients "heard their name being called, someone looking at their back. Sometimes passers-by tried to "get into my head and forbade me to communicate with family and friends" (according to the subjects). Productive social activity declined sharply. Patients either stopped communicating with all their acquaintances or did not leave the house. Or they made impulsive trips to unfamiliar places, they could monotonously follow the same route, for example, riding the subway for many hours in a row, which "calmed their nerves." The psychotic episode consisted of psychomotor agitation, uncontrolled anxiety, and clinical manifestations of hallucinatory-delusional syndrome." During the interictal period, negative personality changes increased against the background of a decrease in adaptive-compensatory functions. The patients became lacking in initiative, their range of interests narrowed to satisfying the simplest everyday needs. They were dependent on relatives. They often complained of somatic discomfort, weakness, and diffuse pain in the body, which was not confirmed by objective research data. They showed unmotivated aggression towards loved ones, while, as the patients themselves noted, "they liked to watch the suffering of their close relatives." Occasionally they experienced feelings of anxiety, depression, and abstract thoughts about death. They had no permanent interests, no plans for the future. There was no criticism of one's condition or determination to seek treatment. Such changes in the domestic (Russian) school of psychiatry are considered as manifestations of negative disorders of the tonic type [30]. Any deviation from the habitual way of life caused protest from the patients. Such a trigger could be the desire of relatives to expand the range of household responsibilities, for example, maintaining personal hygiene, daily routine, cleaning the house, as well as the need to regularly take medications, and participate in psychotherapy. The patients' mood of protest, irritability, and conflict increased. To resolve a conflict situation, patients inflicted superficial self-cuts on themselves, less often inserted various objects under the skin, or burned the skin. At the same time, the actual NAAA were applied impulsively, according to the "last straw" principle, which served as an emotional release and was accompanied by formal regret about what they had done. These characteristics of NAAA, in combination with negative changes of the tonic type, formed the ideational pattern of NAAB.

Research results: The frequency of exacerbation of psychotic symptoms in patients taking risperidone monotherapy was 2.3 cases in the retrospective period and 1.2 cases in the prospective period ($F_{1.92}$, $p < 0.05$). In patients taking combination therapy "risperidone + choline alfoscerate" this indicator was 2.2 and 1.0 cases ($F_{2.2}$, $p < 0.05$). Among patients taking combination therapy "risperidone + memantine", the frequency of psychotic episodes was 2.3 and 0.9 cases ($F_{2.3}$, $p < 0.05$). Finally, for patients taking combination therapy "risperidone + choline alfoscerate + memantine" this figure was 2.3 cases in the retrospective period and 0.9 cases in the prospective period ($F_{2.56}$, $p < 0.01$).

The ability of all drugs included in the study to reduce the severity of negative disorders, which differed in severity, was established. In patients on risperidone monotherapy, the reduction in the severity of negative disorders was at the trend level throughout the study (Table 1): The effectiveness of therapy according to the scale for assessing negative symptoms in patients taking risperidone monotherapy (in points). Table N1

Psychopathological manifestations	Steps to evaluate therapy		
	1 week	12 week	24 week
Flattening and rigidity of affect	33,1	28,1 (F0.08, p>0,05)	23,2 (F1.43, p>0,05)
Speech disorders	22,1	19,4 (F1.14, p>0,05)	18,1 (F1.22, p>0,05)
Apatho-abulic disorders	19,5	15,6 (F1.25, p>0,05)	13,5 (F1.44, p>0,05)
Anhedonia – asociality	15,4	13,4 (F1.15, p>0,05)	12,4 (F1.24, p>0,05)
Attention	12,2	11,2 (F1.09, p>0,05)	8,4 F 1.45, p>0,05

* p≤0,05

The decrease in the severity of negative disorders observed in patients taking combination therapy “risperidone + choline alfoscerate” was at the level of trends throughout the study (Table 2).

The effectiveness of therapy according to the scale for assessing negative symptoms in patients taking combination therapy with risperidone and choline alfoscerate (in points). Table N2

Psychopathological manifestations	Steps to evaluate therapy		
	1 week	12 week	24 week
Flattening and rigidity of affect	33,3	28,0 (F1.19, p>0,05)	23,1 (F1.44, p>0,05)
Speech disorders	22,2	19,1 (F1.16, p>0,05)	18,0 (F1.23, p>0,05*)
Apatho-abulic disorders	19,2	15,3 (F1.25, p>0,05)	12,8 (F1.5, p>0,05)
Anhedonia – asociality	15,2	13,2 (F1.15, p>0,05)	12,3 (F1.24, p>0,05)
Attention	12,3	11,1 (F1.11, p>0,05)	8,3 F1.48, p>0,05

* p≤0,05

Among patients taking combination therapy “risperidone + memantine”, the greatest effect was achieved in terms of reducing psychopathological manifestations associated with apatho-abulic manifestations, reaching statistically significant values by week 24 of the study. Positive changes in relation to other negative disorders remained at the trend level throughout the study (Table N3).

The effectiveness of therapy according to the scale for assessing negative symptoms

in patients taking combination therapy with risperidone and memantine (in points). Table N3

Psychopathological manifestations	Steps to evaluate therapy		
	1 week	12 week	24 week
Flattening and rigidity of affect	33,1	27,3 (F1.21, p>0,05)	21,0 F1.58, p>0,05
Speech disorders	22,1	18,2 (F1.21, p>0,05)	14,1 F1.57, p>0,05
Apatho-abulic disorders	19,1	14,0 (F1.36,	9,7 (F1.97,

		p>0,05	p<0,05*
Anhedonia – asociality	15,4	13,0 (F1.18, p>0,05	9.2 F1.18, p>0,05
Attention	12,6	10.2 (F1.24, p>0,05	7.1 F1.77, p>0,05

* p<0,05

Finally, in patients who took combination therapy “risperidone + choline alfoscerate + memantine,” the greatest effect was achieved in relation to psychopathological manifestations in the form of flattening and rigidity of affect, a decrease in apatho-abulsive disorders, as well as anhedonia and

concentration. Statistically significant changes in these indicators occurred by week 24 of the study (Table 4).

The effectiveness of therapy according to the scale for assessing negative symptoms in patients taking combination therapy with risperidone + choline alfoscerate + memantine (in points). Table N4

Psychopathological manifestations	Steps to evaluate therapy		
	1 week	12 week	24 week
Flattening and rigidity of affect	32,6	26,2 (F1.24, p>0,05	18,0 (F1.81, p<0,05*
Speech disorders	22,1	17,1 (F1.29, p>0,05	13,2 (F1.67, p>0,05
Apatho-abulsive disorders	19,0	13,0 (F1.46, p>0,05	8,9 F2.13, p<0,05*
Anhedonia – asociality	15,0	10,2 (F1.47, p>0,05	8,1 (F1.85, p<0,05*
Attention	12,8	9,9 (F1.29, p>0,05	6,8 F1.88, p<0,05*

p<0,05*

* p<0,05

The incidence of NAAA in patients taking risperidone monotherapy was 3.3 cases in the retrospective period and 1.6 cases in the prospective period (F 2.06, p<0.05). In patients taking combination therapy “risperidone + choline alfoscerate” this figure was 3.2 and 1.5 cases (F 2.13, p<0.05). Among patients taking combination therapy “risperidone + memantine”, the incidence of NAAA was 3.3 and 1.4 cases (F 2.36, p<0.05). Finally, for patients taking combination therapy “risperidone + choline alfoscerate + memantine” this figure was 3.3 cases in the retrospective period, and 1.1 cases in the prospective period (F 3, p<0.01).

Discussion: As part of a comparative analysis, all declared drugs confirmed their effectiveness. At the same time, differences in the effectiveness of therapy on different elements of the clinical picture of the studied individuals were revealed. It was established that all used treatment regimens contributed to reducing the risk of exacerbation of psychotic symptoms, the effectiveness of which decreased in the following order: “risperidone + choline alfoscerate + memantine” < “risperidone + memantine” < “risperidone + memantine” < “risperidone”. Moreover, in all comparison groups, the observed positive changes became statistically significant by the end of the study. With all other treatment regimens, positive changes remained at trend levels throughout the study. It can be assumed that combination therapy, including the use of all three drugs included in the study, can significantly enhance the antipsychotic effect of the base drug (risperidone), due to the effect on different parts of the pathogenesis of a single schizophrenic process. For example, by enhancing the dopaminolytic effect, reducing the hyperfunction of the glutamatergic and cholinomimetic systems, as well as stopping immunodestructive

processes [32]. It was established that all used treatment regimens contributed to a decrease in the severity of negative disorders, the effectiveness of which decreased in the following order: “risperidone + choline alfoscerate + memantine” < “risperidone + memantine” < “risperidone + memantine” < “risperidone”. As a theoretical basis for the results obtained, the following can be assumed: 1) all the declared drugs individually can have a positive clinical effect, acting on various links in the pathogenesis of processual neurocognitive changes [33]; 2) risperidone has a low anticholinergic potential, which reduces the potential risk of deterioration of cognitive functions [34.]; 3) risperidone is able to act as an agonist of serotonin receptors of the 5-HT_{1A} type, which, according to some researchers, can reduce neurocognitive impairment in schizophrenia [35,36]; 4) memantine modulates the action of the cholinergic system, which, in combination with the use of the cholinomimetic pharmacological agent itself (choline alfoscerate), enhances the phenomenon of neuroplasticity, increasing the conductivity of the nerve impulse. At the same time, choline alfoscerate can act as a protector of the negative effects of memantine, including in the prevention of the so-called “Olney's lesion” [37]. It was found that all antipsychotics included in the study reduced the severity of behavioral disorders, including a decrease in the frequency of NAAA, in terms of effectiveness, arranged in the following order: “risperidone + choline alfoscerate + memantine” < “risperidone + memantine” < “risperidone + memantine” < “risperidone”. Such results have an ambiguous explanation. It can be assumed that in some cases NAAAs appear in the structure of behavioral disorders associated with the group of positive disorders. At the same time, forming a stable model of behavior, NAAB reflect a radical restructuring of mental activity and a

decrease in the functions of social adaptation. The pathogenetic basis of such changes are procedural neurocognitive changes. Both hypotheses require further research. At the same time, within the framework of the empirical approach and knowledge of the pharmacodynamic profile of the drugs included in the study, one can expect a positive clinical effect from their use in relation to both hypotheses of the origin of NAAB. The results obtained cannot be considered final. This is hampered by a small sample, the non-randomized nature of the studies, a limited period of observation of the subjects, and the use of a limited number of drugs.

Conclusions: The use of combined treatment regimens, including risperidone and nootropic drugs (choline alfoscerate, memantine), is clinically justified in patients with paranoid schizophrenia with the ideation pattern of NAAB. Combination therapy is superior to antipsychotic monotherapy in reducing the severity of positive and negative disorders, including non-suicidal autoaggression. As part of the actual combination therapy, simultaneous administration of risperidone and two nootropic drugs (memantine and choline alfoscerate) is preferable.

References

1. Kravchenko IV, Sevrykov VT, Bezmenova NO. (2023). Changes in Adaptive-Compensatory Functions in Patients with Paranoid Schizophrenia with an Affective Pattern of Non-Suicidal Auto-Aggressive Behavior in Conditions of Prolonged Social Isolation. *Psychol Psychother Res Stud*. 6(5). PPRS. 000647. DOI: 10.31031/PPRS.2023.06.000647
2. Parsons CG, Stvffler A, Danysz W. (2007). Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system—too little activation is bad, too much is even worse. *Neuropharmacology*.53(6):699-723
3. Rammes G, Danysz W, Parsons CG. (2008). Pharmacodynamics of memantine: an update. *Curr Neuropharmacol*. 6(1):55-78
4. Stone JM, Morrison PD, Pilowsky LS. (2007). Glutamate and dopamine dysregulation in schizophrenia—a synthesis and selective review. *J Psychopharmacol*. 21(4):440-452.
5. Seeman P, Caruso C, Lasaga M. (2008). Memantine agonist action at dopamine D2High receptors. *Synapse*. 62(2):149-153
6. Iwamoto K, Ikeda K, Mizumura S, Tachiki K, Yanagihashi M, Iwasaki Y. (2014). Combined treatment of methylprednisolone pulse and memantine hydrochloride prompts recovery from neurological dysfunction and cerebral hypoperfusion in carbon monoxide poisoning: a case report. *J Stroke Cerebrovasc Dis*.23(3):592-595. doi: 10.1016/j.jstrokecerebrovasdis.2013.05.014. Epub 2013 Jun 19. PMID: 23791468.
7. Kishi T, Mukai T, Matsuda Y, et al. (2014). Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review. *Neuromolecular Med*. 16(1):61-69.
8. Plitman E, Nakajima S, de la Fuente-Sandoval C, et al. (2014). Glutamate-mediated excitotoxicity in schizophrenia: a review. *Eur Neuropsychopharmacol*. 24(10):1591-1605
9. Kishi T, Matsuda Y, Iwata N. (2017). Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. *Psychopharmacology (Berl)*. 234(14):2113-2125
10. Uno Y, Coyle JT. (2019). Glutamate hypothesis in schizophrenia. *Psychiatry Clin Neurosci*.73(5):204-215. doi: 10.1111/pcn.12823. Epub 2019 Mar 6. PMID: 30666759.
11. Snyder MA, Gao WJ. (2019). NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms. *Schizophr Res*. 217:60-70. doi: 10.1016/j.schres.2019.03.010. Epub 2019 Apr 9. PMID: 30979669; PMCID: PMC7258307.
12. Schaefer M, Sarkar S, Theophil I, et.al. (2020). Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. *Pharmacopsychiatry*.53(1):21-29. doi: 10.1055/a-0970-9310. Epub 2019 Aug 7. PMID: 31390660.
13. Molina JL, Voytek B, Thomas ML, et.al. (2020). Memantine Effects on Electroencephalographic Measures of Putative Excitatory/Inhibitory Balance in Schizophrenia. *Biol Psychiatry Cogn Neurosci Neuroimaging*. ;5(6):562-568. doi: 10.1016/j.bpsc.2020.02.004. Epub 2020 Feb 22. PMID: 32340927; PMCID: PMC7286803.
14. Kruse AO, Bustillo JR. (2022). Glutamatergic dysfunction in Schizophrenia. *Transl Psychiatry*.12(1):500. doi: 10.1038/s41398-022-02253-w. PMID: 36463316; PMCID: PMC9719533.
15. Nakahara T, Tsugawa S, Noda Y, et.al. (2022). Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies. *Mol Psychiatry*.27(1):744-757. doi: 10.1038/s41380-021-01297-6. Epub 2021 Sep 28. PMID: 34584230.
16. Matrone M, Kotzolidis GD, Romano A, et.al. Treatment-resistant schizophrenia: Addressing white matter integrity, intracortical glutamate levels, clinical and cognitive profiles between early- and adult-onset patients. *Prog Neuropsychopharmacol Biol Psychiatry*.114:110493. doi: 10.1016/j.pnpbp.2021.110493. Epub 2021 Dec 7. PMID: 34883221.
17. Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S. et al. (2008). Galantamine for the treatment of cognitive impairments in people with schizophrenia. *Am J Psychiatry*. 2008 Jan;165(1):82-9. doi: 10.1176/appi.ajp.2007.07050724. Epub 2007 Nov 6. PMID: 17986678.
18. Kumar PNS, Mohemmedali SP, Anish PK, Andrade C. (2017). Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia. *Indian J Psychiatry*.59(2):219-224. doi: 10.4103/psychiatry.IndianJPsychiatry_133_16. PMID: 28827871; PMCID: PMC5547865.
19. Santos B, González-Fraile E, Zabala A, Guillén V, Rueda JR. et al. (2018). Cognitive improvement of acetylcholinesterase inhibitors in schizophrenia. *Journal of Psychopharmacology*. 32(11):1155-1166. doi:10.1177/0269881118805496
20. Wang GH, Man KKC, Chang WH, Liao TC, Lai EC. (2021). Use of antipsychotic drugs and cholinesterase inhibitors and risk of falls and fractures: self-controlled case series. *BMJ*. 374:n1925. doi: 10.1136/bmj.n1925. PMID: 34503972; PMCID: PMC8427404.
21. Rezaei F, Mohammad-Karimi M, Seddighi S, et al. (2013). S. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study. *J Clin Psychopharmacol*.33(3):336-42. doi: 10.1097/JCP.0b013e31828b50a7. PMID: 23609382
22. Paraschakis A. (2014). Tackling negative symptoms of schizophrenia with memantine. *Case Rep Psychiatry*.2014:384783. doi: 10.1155/2014/384783. Epub 2014 Apr 10. PMID: 24818033; PMCID: PMC4003755.

23. Hassanpour F, Zarghami M, Mouodi S, M et al. (2019). Adjunctive Memantine Treatment of Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Study. *J Clin Psychopharmacol.* 39(6):634-638. doi: 10.1097/JCP.0000000000001115. PMID: 31688396.
24. Kikuchi T. (2020). Is Memantine Effective as an NMDA-Receptor Antagonist in Adjunctive Therapy for Schizophrenia? *Biomolecules.* 10(8):1134. doi: 10.3390/biom10081134. PMID: 32751985; PMCID: PMC7466074.
25. Lopes JP, Tarozzo G, Reggiani A, Piomelli D, Cavalli A. (2013). Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity. *Brain Behav.* 3(2):67-74. doi: 10.1002/brb3.118. Epub 2013 Jan 11. PMID: 23532860; PMCID: PMC3607148
26. Geerts H, Roberts P, Spiros A. (2015). Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology. *Front Pharmacol.* 6:198. doi: 10.3389/fphar.2015.00198. PMID: 26441655; PMCID: PMC4585031.
27. Koola MM. (2018). Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia. *Mol Neuropsychiatry.* 4(3):134-148. doi: 10.1159/000494495. Epub 2018 Nov 19. PMID: 30643787; PMCID: PMC6323397.
28. Koola MM, Praharaj SK, Pillai A. (2019). Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia. *Curr Behav Neurosci. Rep.* 6(2):37-50. doi: 10.1007/s40473-019-00174-5. Epub 2019 May 17. PMID: 32601581; PMCID: PMC7323923.
29. Koola MM. (2021). Alpha7 nicotinic-N-methyl-D-aspartate hypothesis in the treatment of schizophrenia and beyond. *Hum Psychopharmacol.* 36(1):1-16. doi: 10.1002/hup.2758. Epub 2020 Sep 23. PMID: 32965756.
30. Neznanov NG, Ivanov MV (2021). Negative and cognitive disorders in endogenous psychoses: Diagnostics, clinic, therapy, MED Press-Inform Publishers, Moscow, Russia, p. 32
31. Kravchenko IV, Sevryukov VT. (2022). The Focus of the Researcher: Non-Suicidal Auto Aggression. *Inf J. Neuropsych. Beh. Sci.* 3(1):1-3. DOI: 10.51626/ijnbs.2022.03.00026
32. Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O. et al. (2020). The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. *NPJ Schizophr.* 6(1):1. doi: 10.1038/s41537-019-0090-z. PMID: 31911624; PMCID: PMC6946650].
33. Seidman LJ, Mirsky AF. (2017). Evolving Notions of Schizophrenia as a Developmental Neurocognitive Disorder. *J Int Neuropsychol. Soc.* 23(9-10):881-892. doi: 10.1017/S1355617717001114. PMID: 29198285.
34. Sánchez P, Álamo C, Almendros M, Schlueter M, Tasoulas A, Martínez J. (2023). Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM®: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies. *Ann Gen Psychiatry.* 22(1):33. doi: 10.1186/s12991-023-00464-z. PMID: 37660132; PMCID: PMC10474682
35. Díaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P. et al. (2005). Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. *J Neurosci.* 25(47):10831-43. doi: 10.1523/JNEUROSCI.2999-05.2005. PMID: 16306396; PMCID: PMC6725886.
36. Yamada R, Wada A, Stickley A, Yokoi Y, Sumiyoshi T. (2023). Augmentation therapy with serotonin1A receptor partial agonists on neurocognitive function in schizophrenia: A systematic review and meta-analysis. *Schizophr Res Cogn.* 34:100290. doi: 10.1016/j.scog.2023.100290. PMID: 37732133; PMCID: PMC10507645];
37. Olney, J. W.; Labruyere, J.; Wang, G.; Wozniak, D. F.; Price, M. T. et al. (1991). "NMDA Antagonist Neurotoxicity: Mechanism and Prevention". *Science.* 254 (5037): 1515-1518.
38. Vinnikova Irina Nikolaevna. Doctor of Medical Sciences, professor, doctor of the highest category. Federal State Budgetary Institution "National Medical Research Center for Psychiatry and Narcology named after V. P. Serbsky" of the Ministry of Health of the Russian Federation
39. Kravchenko Igor Vladimirovich. Candidate of Medical Sciences, doctor of the highest category, psychiatrist, psychotherapist, clinical pharmacologist of the interdistrict center for medical rehabilitation at the State Budgetary Healthcare Institution "Polyclinic N38". Medical lawyer. Saint-Petersburg, Russia. Email address: www.igorkravchenk@mail.ru; <https://orcid.org/0000-0003-2748-620X>; mob. tel. 89213767134

Ready to submit your research? Choose ClinicSearch and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At ClinicSearch, research is always in progress.

Learn more <http://clinicsearchonline.org/journals/clinical-reviews-and-case-reports>



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.